Testosterone treatment of hypogonadal men participating in competitive sports

被引:9
作者
Gooren, L. J. [1 ]
Behre, H. M. [2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands
[2] Univ Halle Wittenberg, Univ Hosp Halle, Ctr Reprod Med & Androl, Halle, Germany
关键词
sports; testosterone levels; testosterone undecanoate;
D O I
10.1111/j.1439-0272.2008.00838.x
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Testosterone has a steeply dose-dependent effect on muscle mass and strength irrespective of gonadal status. So, for reasons of fairness, people who engage in competitive sports should not administer exogenous testosterone raising their blood testosterone levels beyond the range of normal. There is a ban on exogenous androgens for men and women in sports, but an exception has been made for men with androgen deficiency due to pituitary or testicular disease. Men who receive testosterone administration for the indication hypogonadism have an interest in the use of testosterone preparations generating blood testosterone levels within the normal range of healthy, eugonadal men. On the grounds of a positive correlation between blood testosterone concentrations muscle and volume/strength, they are best served with a parenteral testosterone preparation, rather than transdermal testosterone, but they should not run the risk of being excluded from competition because of supraphysiological testosterone levels. The latter is a realistic risk with the traditional parenteral testosterone esters. The new parenteral testosterone undecanoate preparation offers much better perspectives. Its pharmacokinetics have been investigated in detail and there is a fair degree of predictability of resulting blood testosterone levels with use of this preparation.
引用
收藏
页码:195 / 199
页数:5
相关论文
共 21 条
  • [1] Important effect of food on the bioavailability of oral testosterone undecanoate
    Bagchus, WM
    Hust, R
    Maris, F
    Schnabel, PG
    Houwing, NS
    [J]. PHARMACOTHERAPY, 2003, 23 (03): : 319 - 325
  • [2] Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism:: phase I studies
    Behre, HM
    Abshagen, K
    Oettel, M
    Hübler, D
    Nieschlag, E
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (05) : 414 - 419
  • [3] Behre HM, 2004, TESTOSTERONE ACTION, P405
  • [4] Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle
    Bhasin, S
    Woodhouse, L
    Casaburi, R
    Singh, AB
    Mac, RP
    Lee, M
    Yarasheski, KE
    Sinha-Hikim, I
    Dzekov, C
    Dzekov, J
    Magliano, L
    Storer, TW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) : 678 - 688
  • [5] The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
    Bhasin, S
    Storer, TW
    Berman, N
    Callegari, C
    Clevenger, B
    Phillips, J
    Bunnell, TJ
    Tricker, R
    Shirazi, A
    Casaburi, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) : 1 - 7
  • [6] Testosterone dose-response relationships in healthy young men
    Bhasin, S
    Woodhouse, L
    Casaburi, R
    Singh, AB
    Bhasin, D
    Berman, N
    Chen, XH
    Yarasheski, KE
    Magliano, L
    Dzekov, C
    Dzekov, J
    Bross, R
    Phillips, J
    Sinha-Hikim, I
    Shen, RQ
    Storer, TW
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06): : E1172 - E1181
  • [7] Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
    Bhasin, S
    Storer, TW
    Berman, N
    Yarasheski, KE
    Clevenger, B
    Phillips, J
    Lee, WP
    Bunnell, TJ
    Casaburi, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 407 - 413
  • [8] EFFECTS OF ANABOLIC-ANDROGENIC STEROIDS ON MUSCULAR STRENGTH
    ELASHOFF, JD
    JACKNOW, AD
    SHAIN, SG
    BRAUNSTEIN, GD
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) : 387 - 393
  • [9] Androgen replacement therapy - Present and future
    Gooren, LJG
    Bunck, MCM
    [J]. DRUGS, 2004, 64 (17) : 1861 - 1891
  • [10] Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport
    Handelsman, DJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05) : 1646 - 1653